Adaptimmune, a biotech stock, holds promise with potential FDA approval, valued at over 100 billion. As Associate Director of Global Regulatory Affairs, Cramer oversees CMC compliance, ensuring regulatory standards are met. Investors eyeing penny stock opportunities should consider Adaptimmune before a potential massive buyout.